Nomogram to Predict Breast Cancer Related Lymphedema

Overview

It has been hypothesized that damaged arm lymphatic drainage is associated with the arm lymphedema after axillary lymph node dissection (ALND). However, the majority of breast cancer patients with complete ALND has not suffered from arm lymphedema, which appears to be due to the residual arm lymph nodes that has not been removed in the axillary dissection. With the compensation of the residual arm lymph flow above the level of axillary vein, the arm lymphatic drainage could keep balance and remain normal function. This arm lymphedema prediction model that included the protective factor, the proportion of arm lymph flow above the level of axillary vein, allows intraoperative intervention to be performed for the high-risk group. The arm lymphatics of these distinguished patients would be preserved to eliminate the occurrence of arm lymphedema in this study.

Full Title of Study: “Intraoperative Nomogram to Predict Breast Cancer- Related Lymphedema Based in Artificial Intelligence Image Recognition: a Randomized Controlled Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 31, 2022

Interventions

  • Procedure: Axillary surgery based on lymphedema prediction nomogram
    • Based on the intraoperative lymphedema prediction nomogram, individualized treatment was recommended to breast cancer patients with different level of risk. For patients with low possibility of developing breast cancer related lymphedema, it was not necessary to preserve arm lymphatics. While the breast cancer patients who were performed mastectomy and ALND with 28 kg/m2 prepared to receive taxane-based chemotherapy, supraclavicular and infraclavicular radiotherapy, according to the established intraoperative nomogram, the proportion of the arm lymph flow above the axillary vein needed to exceed 52%. Otherwise, the arm lymphatics should be identified and preserved.

Arms, Groups and Cohorts

  • Experimental: Axillary surgery based on lymphedema prediction nomogram
    • Based on the intraoperative lymphedema prediction nomogram, individualized treatment was recommended to breast cancer patients with different level of risk. For patients with low possibility of developing breast cancer related lymphedema, it was not necessary to preserve arm lymphatics. While the breast cancer patients who were performed mastectomy and ALND with 28 kg/m2 prepared to receive taxane-based chemotherapy, supraclavicular and infraclavicular radiotherapy, according to the established intraoperative nomogram, the proportion of the arm lymph flow above the axillary vein needed to exceed 52%. Otherwise, the arm lymphatics should be identified and preserved.
  • No Intervention: Standard axillary lymph node dissection
    • Standard axillary lymph node dissection was performed with complete resection of Berg’s levels I and II.

Clinical Trial Outcome Measures

Primary Measures

  • Rate of arm lymphedema
    • Time Frame: Up to 5 years
    • A difference in volume between the arms < 10% was defined as lymphedema
  • Rate of locoregional recurrence
    • Time Frame: Up to 5 years
    • Locoregional recurrence included local recurrence and regional recurrence. Local recurrence was defined as chest wall recurrence of breast cancer, and regional recurrence was defined as the axilla recurrence of breast cancer
  • Rate of distant metastasis
    • Time Frame: Up to 5 years
    • Cancer cells from breast metastasized to other organs.

Participating in This Clinical Trial

Inclusion Criteria

  • Patients aged 18 years or older with T1-3 invasive breast cancer; – Clinically node-positive breast cancer, defined as positive on preoperative axillary palpation, ultrasound examination, and computed tomography scan with contrast; – Patients who underwent mastectomy with a positive sentinel lymph node (SLN); – Patients who underwent breast-conserving surgery containing more than two positive SLNs. Exclusion Criteria:

  • Neoadjuvant chemotherapy; – Previous history of breast cancer.

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Wuhan University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Gaosong Wu, Ph D, MD, Director – Wuhan University
  • Overall Official(s)
    • Gaosong Wu, Ph.D., Principal Investigator, Wuhan University
  • Overall Contact(s)
    • Qianqian Yuan, M.D., 13026322297, Yuanqq11@whu.edu.cn

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.